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Abstract Recently there have been some developments
in the preparation of controlled drug delivery systems for
glaucoma. Many materials are being used in this area,
namely gelatine and chitosan. Both of them present high
levels of biocompatibility and biodegradability. In this
paper, we wish to report the work we have been doing on
the preparation and characterization of hydrogels based on
gelatine and chitosan. The crosslinking agents used were 1-
(3-(Dimethylamino)propyl)-3-Ethylcarbodiimide hydro-
cholide (CDI), 1,4-Butanodiol diglycidyl ether (epoxyde
1), Ethylene glycol diglycidyl ether (epoxyde 2) and gen-
ipin. The results obtained showed that all of the films were
hydrogels. The surface and transversal cut showed a porous
surface in all the films. The thermal analysis proved the
modifications in the polymeric chains, with the stabiliza-
tion of all of them by the crosslinking agents. The release
pattern indicates that the gelatine films were the best since
they release the adequate proportion of drug. Finally, the
cytotoxicity showed that the gelatine films were all bio-
compatible, specially the ones crosslinked with one of the
Epoxydes.
Introduction
Glaucoma is one of the diseases that affect the internal
human eye. It is due to an increase of the intraocular
pressure (IOP) which results from the production and
drainage of the aqueous humour. In its worst case it can
lead to total loss of vision by the patient [1].
The most common type of glaucoma is the primary
open angle that can be treated by topical administration
of drugs, namely beta-blockers (such as Timolol, Be-
taxolol or Latanoprost), associated with another type of
drugs to control the IOP, such as Pilocarpina [2, 3]. Due
to the working mechanism of the eye, the quantity of
drugs that really reaches the local of activity is very low
(normally 5%) [3]. So, to maintain the concentrations of
the drug, it is necessary that the patient make many
applications during the day. To avoid this situation, drug
delivery systems have been developed. These systems
are characterized by the ability of releasing the right
proportion of drug during long periods of time. Besides
the drug can be delivered in the right place in the body
[4].
The liberation can occur in many ways, namely due to
controlled diffusion of the drug through the film porous, or
due to the degradation of the polymeric matrix [5].
When the release occurs in accordance with the diffu-
sion process of the drug, the diffusion parameters can be
calculated. For this purpose, Fick’s 1st law has to be
applied [6]:
JA ¼ DA;B dCA
dx
; ð1Þ
where, JA represents the molar flux of the substance A,
express in mg/(m2s), DA,B is the diffusion coefficient of A
in B, express in m2/s and dCA/dx is the gradient of
concentrations of substance A on a specific axel. In this
case study, after the beginning of the release, the
concentrations of the drug in both sides of the film
change. So the gradient is not constant and, in the limit, it
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will reach zero. Therefore in accordance with the second
Fick’s Law:
dCA
dt
¼ DA;B d
2CA
dx2
ð2Þ
Rearranging the expression, the value of the coefficient
of diffusion can be calculated:
Mt
M1
¼ 4
p
1
2
ffiffiffiffiffi
Dt
l20
s
; ð3Þ
where M¥ is the total amount of drug used in the prepa-
ration of the system, Mt the amount of drug released in a
time t, and l0 is half the film’s thickness. This expression is
valid for Mt/M¥ < 0.5.
Several polymers, e.g. PVA, PVP, chitosan and gelatine
[7–9], have been used in the development of drug delivery
systems.
These polymers can be considered as hydrogels, solu-
tions of hydrophilic polymers, with great capacity of water
absorption [10, 11]. In order to crosslink the above poly-
mers, various crosslinking agents have been used, like
polyepoxydes [12], Genipin [13, 14], N-N¢-Carbon-
ilodiimidazol or Carbodiimide [15, 16].
The present paper describes new ways to modify both
chitosan and gelatine, in order to prepare new films to be
used as drug delivery systems. The films were character-
ized in different ways, namely, their swelling rate, and their
thermal transitions. The surface and the transversal cuts
were also characterized by SEM. Finally, we present the
results for the drug delivery kinetics and the cytotoxicity of
the gelatine membranes.
Materials and methods
Materials
Gelatine from porcine skin (EC 232-554-6) was purchased
from Sigma (Steinheim, Germany). Chitosan, (medium
molecular weight), 1-(3-(Dimethylamino)propyl)-3-Ethyl-
carbodiimide hydrocholide, 98+% (CDI), 1,4-Butanodiol
diglycidyl ether, tech., 60% (EC 219-371-7) and Ethylene
glycol diglycidyl ether, tech. 50% (EC 218-746-2) were
purchase from Aldrich Chemical Company (Steinheim,
Germany). Genipin, a natural crosslinking agent, was ac-
quired from Challenge Bioprodutcs Co., Ltd.
Acetic Acid, with a degree of purity of 99.5%, was
purchase from BHD-Chemicals Lda (Poole, UK), and
ethanol to dissolve 1,4-Butanodiol diglycidyl ether, was
acquire from Pronolab (Lisbon, Portugal).
The drug used during this study was Timolol Maleate
obtain from Edol (Portugal).
Preparation of the gelatine solution
In order to prepare the gelatine solution, 2 g of gelatine
powder were dissolved in 10 mL of distillate water at
50 C, with mechanical stirring for 20 min.
Preparation of the chitosan solution
In order to prepare a 1.33% solution, 2 g of chitosan were
dissolved in 150 mL of an acetic acid solution at 5% (w/v),
for 24 h at room temperature.
Crosslinking of gelatine
Several gelatine films, with different crosslinking agents,
were prepared. Their composition is indicated in Table 1.
Film 1 was prepared without any crosslinking agent.
This film was considered as a blank test in all the experi-
ments. Membranes 2, 3 and 4 were prepared by adding, to
the 10 mL of the gelatine solution, the CDI, previously
dissolved in a minimal quantity of distillate water to allow
a better dispersion of the crosslinking agent in all the
polymeric solution.
For the membranes crosslinked with Ethylene glycol
diglycidyl ether (epoxyde 2), the procedure was much
easier, because the compound is in the liquid state, which
allows a better dispersion without the needing of a solu-
bilization in water.
Finally, the third crosslinking agent used was genipin, a
natural compound that was added directly to the solution.
Crosslinking of chitosan
The chitosan, in solution, was crosslinked by using two
different crosslinking agents, 1,4-Butanodiol diglycidyl
Table 1 Percentage of three crosslinking agents used in the prepa-
ration of gelatine based films
Film number Crosslinking agent Concentration (W/W) (%)
1 – –
2 CDI 1
3 CDI 2
4 CDI 3
5 Epoxyde 0.2
6 Epoxyde 0.3
7 Epoxyde 1
8 Genipin 1
9 Genipin 2
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ether (epoxyde 1) and Ethylene glycol diglycidyl ether
(epoxyde 2). The concentrations used are presented in
Table 2.
In the preparation of the chitosan films, 10 mL of the
solution previously made were used. Due to the hidrop-
hobicity of epoxyde 1, it was dissolved in an ethanol
solution before the mixing with the chitosan solution under
mechanical stirring. As for epoxyde 2, the method used
was equal to the one used for gelatine. Finally, the last film
was made to serve as a blank test.
Before the introduction of the crosslinking agent, we
put, as for the gelatine films, 5 mg of drug previously
dissolved in water.
In both cases, the drug was immobilized by entrapment,
i.e., it was dissolved in the solutions before addition of the
crosslinking agents.
After the formation of the final solution, we put them
on a petri dish and left to dry to open air, at 20 C during
72 h.
Physical characterisation of the membranes
Swelling ratio determination
All the films, with weights between 200 and 400 mg
were introduced into a beaker containing 400 mL of
physiological serum at 18 C and kept, until constant
weight was achieved. Then the films were clean with
filler paper and weighed every minute for a period of
15 min. From the graph obtained, the initial weight
was evaluated for each experiment. The swelling
capacity was determined by using the following
equation:
%swelling ¼ Mwet  Mdry
Mdry
 100 ð4Þ
where Mwet is the weight of the films after reaching con-
stant weight in serum and Mdry the weight of each films
completely dry.
Morphological analysis (SEM)
The preparation of the samples to SEM was made in three
different steps. First, we removed the water of the samples
by liophilization in vacuum, at temperatures near –50 C.
After 48 h, the samples were put on a metallic support
and covered with gold in order to make the material a good
conductor. Finally, each sample was analysed by SEM on a
JSM-5310.
Thermal Analysis studies (DSC)
The tests of Thermal Analysis were made in a PL-DSC,
with a constant flux of nitrogen of 3–4 mL/s, at a 1,2 bar
pressure. The results were analysed with help of a com-
puter program call Thermal Analysis.
The samples for each test had a weight between 5 and
6 mg and were subject to a heating process from 30 to
200 C, at a constant velocity of 10 C/min. All the sam-
ples were analysed in duplicate.
Study of the releasing kinetic of drugs from the polymeric
films
In this part of the study, the quantification of the amount of
drug released was made with the use of the Ultraviolet
absorption technique with help of a spectrophotometer
Jasco V-530. The films were introduced in a dialysis
membrane to avoid, during the degradation process, any
piece of the film interfering in the reading. Then all films
were put in Erlemeyers containing 100 mL of physiologi-
cal serum. Each assay was carried out at 37 C. The
absorption readings were made after 15 min, 30 min, 1, 2,
3, …, 24, 25, …, 196 h at 294 nm of wavelength.
Biocompatibility and cytotoxicity tests
After the preparation of the films, they were washed with
physiological serum during 24 h, in order to remove any
trace of the crosslinking agent that didn’t react. The weight
of each film was between 10 and 60 mg, and each sample
was made in duplicate. The tests were made with the films
hydrated in order to avoid any absorption of the medium by
the samples. After this wash, they were sterilized with UV
radiations, in a P-Selecta UV Este´ril, at 254 nm during
40 min.
In order to analyse the cytotoxicity of each film, the
SRA 01/04 cells (Epithelial Cells of Lens) and the COS-7
(isolated cells from the suprarenal African Green Monkey)
were chosen. The cells were grown in DMEM (Dulbecco’s
Modified Eagle Medium) with glucose and glutamine ad-
Table 2 Crosslinking agents and their concentrations used in the
chitosan films
Film number Crosslinking agent Concentration (W/W) (%)
10 Epoxyde 1 1
11 Epoxyde 1 2
12 Epoxyde 2 0.2
13 Epoxyde 2 0.5
14 Epoxyde 2 1
15 – –
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ded with 10% of bovine fetal serum and antibiotic estup-
tomicin/penicillin.
The cells were grown at 37 C in a carbon dioxide and
atmosphere and 100% of humidity. The medium was
changed every two days. The cell density in the holes was
0.1 · 106 cells/mL.
For each plate we made a blank test, only with cells and
cell medium. The viability study, with the films in contact
with the cells, was held during 24 h, and the test chosen
was the MTT (M-5655 Thiazolyl Blue). 40 lL of a MTT
solution of 5 mg/mL were added, prepared in PBS (Phos-
fate Buffer Solution) in each hole of the plate. The plate
was then incubated for 2 h during which the MTT was
metabolised by the living cells into an insoluble formazan
compound. The crystals obtained were dissolved in
300 mL of isopropanol acid. From that volume, we took
150 mL to put in the Multiwell Plates with 96 holes and
made an Elisa reading in the spectrophotometer at 450 nm.
Results and discussion
In the first crosslinking reaction, CDI activates –COOH
groups from different aminoacids that lately will crosslink
with –NH2 groups of other aminoacids.
Figures 1 and 2 shows the different reactions for ep-
oxydes and genipin agent.
Swelling ratio determination
The swelling ratio gives a good indication of the hydro-
phobicity/hydrophilicity of the polymer. This was evalu-
ated by using Eq. (4).
The results are indicated in Table 3 for the gelatine films
and in Table 4 for the chitosan films.
The results indicated in Table 3 suggest that the swell-
ing capacity:
(1) Is higher when genipin is used as the crosslinkling
agent.
(2) Decreases with the increasing crosslinking agent
concentration. This could be related to the decreasing
of free –NH2 and –OH groups of the protein as pre-
viously said.
The results indicated in Table 4 show that the swelling
capacity of chitosan is lower than the gelatine’s. This is
related with the lower solubility of the material used and
also due to both the epoxydes, although epoxyde 1 presents
a slightly higher swelling capacity.
The results suggest that, the higher the degree of
crosslinking, the lower the swelling capacity of the films.
This result could be related with the fact that, for high
levels of crosslinking reaction, exist a greater interaction
and linking points between the polymeric chains. So the
polymer becomes much more resistant to water absorp-
tion. We also could verify that, the films after being
crosslinked with the epoxyde 2, presented a lower
absorption capacity when compared with the results for
the other agents. There is only one exception to these
results, and that is the films crosslinked with genipin. The
results showed a greater capacity in the films crosslinked
that in the gelatine film. This can be explained by the
hydrophilicity of the agent.
Fig. 1 Crosslinking reaction between gelatine and chitosan and
epoxydes
Fig. 2 Crosslinking reaction
between gelatine and genipin
Table 3 Swelling capacities for each gelatine film
Film Swelling capacity/% Crosslinking agent
1 797 –
2 696 CDI at 1%
3 608 CDI at 2%
4 645 CDI at 3%
5 356 Epoxyde 2 at 0.2%
6 272 Epoxyde 2 at 0.5%
7 236 Epoxyde 2 at 1%
8 1040 Genipin at 1%
9 967 Genipin at 2%
2312 J Mater Sci: Mater Med (2007) 18:2309–2317
123
Although all the swelling capacities are very high for the
purpose of this study, the increase in volume was much
greater in length and width than in thickness.
Characterization of the films by using Scanning
Electronic Microscopy (SEM)
The samples 1, 2, 5, 8, 10, 12 and 15 were analysed by
Scanning Electronic Microscopy (SEM).
From the image of the surface of gelatine, amplified
2000 times, and the transverse cut, amplified 75, 100 and
500 times, we observed a structure in which the three-
dimensional constitution was a bit collapsed, but with
porous sizes between 10 and 100 lm. We can clearly see a
homogeneous structure (Fig. 3).
The surface analysis of film 2 (Gelatine + CDI at 1%)
shows the structure is very similar to the gelatine films
without any crosslinking agent. In the transversal cut,
amplified 75 and 500 times, we observe a three-dimen-
sional structure forming cocoons with very homogeneous
sizes and structures. We also can see a great exposed sur-
face area, which allows a great contact area between the
films and the drug included, and the fluid around.
The surface image, amplified 2000 times, of the film 5
(Gelatine + Epoxyde 2 at 0.2%), shows a porous surface,
with sizes between 5 and 10 lm. The structures are much
smaller and tight than for film 2.
The images from film 8 (Gelatine + Genipin at 1%),
show a porous surface forming the walls of the bigger
porous. In the transversal cut, we can see images similar to
the ones obtained for the gelatine film although there is a
greater organization in the gelatine + genipin film.
The chitosan film crosslinked with epoxyde 1 presents
porous with constant sizes, approximately 5 lm (Fig. 4).
But, the other chitosan films studied showed porous with
sizes much smaller. This fact can be explained by the
structure of chitosan and the crosslinking agents. In fact the
chemical structure of epoxyde 2 is much smaller than the
one of epoxyde 1. This fact can explain why the porous of
these membranes are smaller.
From all the images, we can suggest that the films ob-
tained presented great porosity. This allows a high contact
area, for the linking of the drug, as well as for its release.
Differential Scanning Calorimetry (DSC)
According to the literature [17], the first glass transition
(Tg) of gelatine occurs around –30 C, associated with
non-rigid blocks, a second transition between 71 C and
75 C, associated with the rigid blocks of the gelatine, and
a third transition around 130 C, corresponding, probably,
to different thermal transitions. The gelatine DSC shows a
glass transition around 75.4 C, visible by the endothermic
Table 4 Swelling capacities for chitosan films
Film Swelling capacity/% Crosslinking agent
10 448 Epoxyde 1 at 1%
11 436 Epoxyde 1 at 2%
12 358 Epoxyde 2 at 0.2%
13 291 Epoxyde 2 at 0.5%
14 146 Epoxyde 2 at 1%
15 577 –
Fig. 3 Surface (a) amplified
2000 times and transversal cut
(b) amplified 500 times of
gelatine film
Fig. 4 Surface amplified 3500 times of Chitosan + Epoxyde 1 at 1%
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depression, caused by the increase of the calorific capacity.
Chart 1 shows the DSC obtained for gelatine.
The DSC of film 2 (Chart 2), shows a small increase of
the third transition peak, moving from 133 C to 141 C.
The peak shows a slight increase of the area, traducing a
greater thermal stability. In film 3, we see a transition at
75 C and another at 150 C. These peaks are less evident
and much wide, fact that increases even more when we
compare with the DSC of film 4.
The film of gelatine (Chart 3) crosslinked with epoxyde
2 at 0.2%, shows a slight increase of the second transition
temperature, from 75.43 C to 88.2 C. We can see a new
peak around 160 C, that can be associated with the
decomposition of the crosslinking agent. For film 6 we
can’t see the peak around 160 C, which, probably means
that the film was not homogenous. The next chart shows
the DSC for Gelatine + epoxyde 2 at 0.2%.
Film 8, gelatine crosslinked with genipin (Chart 4),
presents an increase of the second transition temperature to
85.0 C (Chart 4). The peak around 130 C appears in the
same position as for gelatine, but it has an area slightly
smaller. The peak around 185 C is due to the decompo-
sition of the crosslinking agent.
As for the chitosan films, DSC shows a thermal transi-
tion around 130 C (Chart 5). According to the literature
[18] we can see that this transition is normally ascribe to
the glass transition temperature, although some authors
consider that temperature at 200 C. The differences ob-
tained are usually related with the molecular weight of the
chitosan used. Other transitions also described in the lit-
erature were not observed in this study. This can be ex-
plained due to the different experimental conditions used in
the studies. Those transitions are related with the presence
of water in the chitosan chains.
For films 10 and 11, we can see an increase if the second
transition temperature, which proves the success of the
chemical modification. Furthermore, we can see that film
11, with a greater concentration of crosslinking agent
presents a second transition temperature higher than for
film 10, which gives the idea that the crosslinking exten-
sion is greater for the first film than for the second. Besides
this, we can see a decreasing of the fusion enthalpy which
can mean a decrease in the polymer crystallinity because
we need to supply the sample less energy for the transition
to occur.
For films crosslinked with epoxyde 2 (films 12, 13 and
14), we can see also an increase of the second transition
temperature. The explanation for this fact is equal for the
case of chitosan + epoxyde 1 (films 10 and 11). As for the
enthalpy, we can see that the values are equal for these
systems which can mean that the crystallinity is equal to
chitosan.
As a conclusion, we can see that an increasing of the
crosslinking agents concentration, is accomplish with an
increase of the thermal transitions and the peaks area. This
means that the crosslinking was successful and the chem-
ical reaction was able to stabilize the polymer matrix.
Study of the releasing kinetic of drugs from the
polymeric films
The release kinetics were determined with UV spectros-
copy at 294.5 nm. After that, we made another test, with a
dialysis membrane, to find out the delay caused by the
membrane. For that, we put a drug solution inside a dialysis
Chart 1 DSC of the gelatine film
Chart 2 DSC for gelatine crosslinked with CDI at 1%
Chart 3 DSC of gelatine crosslinked with epoxyde 2 at 0.2%
Chart 4 DSC of gelatine + genipin at 1%
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membrane and made the readings in the spectrophotometer
for different release times. The results suggest that the drug
presented a delay of 2 to 3 h, from its release by the system
and the passing through the dialysis membrane.
Every film, with a weight between 200 and 260 mg was
put inside a dialysis membrane and inside a beaker with
serum.
Charts 6 and 7 show the release pattern of films 5 and
12.
All systems studied showed a similar release pattern
and, as can be seen in both charts all systems follow a
Fickian kinetic pattern with values for the diffusion release
exponent within those considered as Fickian kinetics. As
for the diffusion coefficient we applied Eq. (3) to determine
it value for each system. The results are shown in Table 5.
As we can see from the Table 5, the gelatine film
without any crosslinking agent is the one that presents a
greater diffusion coefficient. This could be related with the
open structure that the gelatine molecule presents. When a
crosslinking agent is added to the gelatine, the diffusion
coefficients begin to get smaller. The same happens with
the chitosan systems. The film that presents the biggest
coefficient is the chitosan film, but, as we can see, it’s
much smaller than the gelatine coefficient. This can be
explain due to the fact that the chitosan chains are not so
open as the gelatine ones.
We made, just for comparison, a study of the release
pattern at 20 C. The results show that the amount of drug
released was much smaller than for the release at 37 C.
This can be related with the degradation of the films at
37 C. So, we can conclude that the release of the drug, at
37 C, is not only due to the diffusion of the drug mole-
cules through the polymeric matrix, but also due to the
degradation of that matrix.
Biocompatibility and cytotoxicity tests
As we refer in the materials section, for these tests we used
two different types of cells, SRA 01/04 and COS-7. Due to
the results presented before, we decided to make these tests
only with the gelatine systems.
Chart 5 DSC of the chitosan film
Chart 6 Release pattern of gelatine + epoxyde 2 at 0.2%
Chart 7 Release pattern for the chitosan and epoxyde 2 at 0.2%
system
Table 5 Diffusion coefficients for Timolol for all the systems studied
Film Diffusion Coefficient
· 105 / (cm2/h)
1 4.27
2 3.18
3 3.23
4 3.63
5 4.09
6 3.50
7 1.05
8 3.28
9 2.42
10 0.213
11 0.154
12 0.671
13 0.327
14 0.308
15 1.05
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For each test, we made a blank with cells only, without
any kind of samples. For these tests we gave 100% viability
and compared the other results with these ones. The results
for the SRA cells are shown in Chart 8.
For each film we made three tests, using first 10 mg of
each film, then 30 mg and finally 60 mg.
As we can see from the figure, the gelatine film without
any crosslinking agent presents high levels of viability.
But, for 60 mg of gelatine film we see a decrease in the
viability. This can be related to the fact that the levels of
pH dropped in this test, so we can conclude that gelatine, in
high amounts make the medium much more acid.
The films of gelatine crosslinked with CDI, present a
drop in the levels of viability. But, for lower concentra-
tions, we can still see high levels of viability. It’s important
to refer at this point that some results may show the con-
trary to what we are saying but that is due to some lack of
homogeneity in the film. That is the case with the results of
film 3, where the sample with 30 mg of film presents the
higher viability. This problem with the viability is less
influent in the case of gelatine crosslinked with epoxyde 2.
For this case, we can see high levels of viability, although
the crosslinking agent is toxic. This result was a surprise
because, for all the concentrations, we observed high levels
of viability, so, we can conclude that all of the epoxyde was
linked to the polymeric chain. But, as expected, when the
concentration of epoxyde increases, the levels of biocom-
patibility decreases, but to levels higher than for gelatine
crosslinked with CDI.
Finally, for the system Gelatine + Genipin, we observed
that the levels of biocompatibility were much smaller than
expected, especially when the concentration of genipin
increases from 1% to 2%. The only explanation that we can
give is probably many molecules of genipin didn’t react
and made the system less viable than the others studied.
So, we can conclude that cytotoxicity of all the systems
is, generally, very low, especially the system gela-
tine + epoxyde 2.
As for the COS-7 the method used was the same but
with only one amount of each system (30 mg). The results
are presented in Chart 9.
As we can see from the figure above, the results show
that the viability is, like with the SRA cells, high. Once
again the results for the system gelatine + epoxyde are the
best ones, even better than for gelatine films. For these
cells, the worst result is for the gelatine + CDI system.
Theses results show us that SRA cells are much sensi-
tive than the COS-7, because the viability level for the first
cells is much worst than for the COS-7. But, for either type
of cells, the levels obtained were very high.
Conclusions
From this study, we can suggest that, both gelatine and
chitosan are good materials for drug delivery systems. We
can also say that the method used to modify both materials
was good, and the crosslinking was successful. As for the
results, we can clearly see that, for all the gelatine systems,
the amount of drug released for 7 days was the enough to
treat the disease, and also we’ve observed that the degra-
dation process was well under way at that time. The
chitosan systems presented a release pattern much slower
to the one we were looking for.
The cytotoxicity of all gelatine systems was very low,
especially for the system gelatine + epoxyde 2, which is
the one that presents the best results in all characterizations
made. The result with the COS-7 cells gives the option to
use these systems in other applications than ophthalmo-
logic ones.
Chart 8 Viability results for the SRA cells
Chart 9 Results of the viability for COS-7 cells
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